Home DNA Damage/DNA Repair DNA/RNA Synthesis inhibitor Amenamevir

research use only

Amenamevir DNA/RNA Synthesis inhibitor

Cat.No.S5552

Amenamevir (ASP2151) is a potent helicase-primase inhibitor and a novel class of antiviral agent.
Amenamevir DNA/RNA Synthesis inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 482.55

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 482.55 Formula

C24H26N4O5S

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 841301-32-4 -- Storage of Stock Solutions

Synonyms ASP2151 Smiles CC1=C(C(=CC=C1)C)N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4

Solubility

In vitro
Batch:

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
helicase-primase [1]
In vitro
ASP2151 inhibited the in vitro replication of HSV-1. The mean EC50s of ASP2151 against HSV-1 and HSV-2 were 14 (range, 7.7 to 20) and 30 ng/ml (range, 15 to 58), respectively[2].
In vivo
In the cutaneously HSV-1-infected mouse model, ASP2151 dose dependently suppressed intradermal HSV-1 growth, with the effect reaching a plateau at a dose of 30 mg/kg of body weight/day[2].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02223351 Completed
Healthy
Maruho Europe Limited
 September 2014 Phase 1
NCT00487682 Completed
Herpes Zoster
Astellas Pharma Inc
 November 13 2007 Phase 2
NCT00486200 Completed
Herpes Genitalis
Astellas Pharma Inc
 June 21 2007 Phase 2
NCT02796118 Completed
Healthy Subjects
Astellas Pharma Inc
 July 2006 Phase 1
NCT02852876 Completed
Herpes Genitalis|Herpes Zoster
Astellas Pharma Europe Ltd.|Astellas Pharma Inc
 September 2005 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map